Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804640 | 0.88 | ADAMTS4 (0.51) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL10529091 | 0.81 | CA1 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL6554634 | 0.80 | GAA (0.59) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL6828427 | 0.78 | CA1 (0.61) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL29288589 | 0.78 | CA1 (0.55) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3062734 | 0.78 | ALDH1A1 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL6228003 | 0.78 | CA1 (0.55) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL29095319 | 0.78 | BCAT1 (0.53) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL29288594 | 0.78 | CA2 (0.55) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL13527537 | 0.78 | MMP2 (0.66) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113234029-B | Synthesis method of 2-amino-3, 5-dihalogen pyrazine | 白银康寓信生物科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113234029-A | Synthesis method of 2-amino-3, 5-dihalogen pyrazine | 白银康寓信生物科技有限公司 | 2021-08-10 | — | — | CN | claimed |
| CN-113087687-A | Method for direct carbon-hydrogen alkynylation of thioamide-oriented aromatic hydrocarbon | 宁夏大学 | 2021-07-09 | — | — | CN | claimed |
| US-20190046513-A1 | COMBINATION THERAPIES OF HDAC INHIBITORS AND TUBULIN INHIBITORS | R-BRIDGE INVESTMENT SIX PTE. LTD. (SG) | 2019-02-14 | — | — | US | claimed |
| WO-2019032769-A1 | COMBINATION THERAPIES OF HDAC INHIBITORS AND TUBULIN INHIBITORS | HUYA BIOSCIENCE INTERNATIONAL, LLC (US) | 2019-02-14 | — | — | WO | claimed |
| WO-2018119190-A1 | MICROTUBULE POLYMERIZATION MODULATORS FOR TREATING LMNA-RELATED DILATED CARDIOMYOPATHY | NORTWESTERN UNIVERSITY (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180169040-A1 | MICROTUBULE POLYMERIZATION MODULATORS FOR TREATING LMNA-RELATED DILATED CARDIOMYOPATHY | NORTHWESTERN UNIVERSITY (US) | 2018-06-21 | — | — | US | claimed |
| US-20180147044-A1 | TUBULAR WOVEN CONSTRUCT | TORAY INDUSTRIES, INC. (JP) | 2018-05-31 | — | — | US | claimed |
| EP-3305336-A1 | TUBULAR WOVEN FABRIC STRUCTURE | Toray Industries, Inc. (JP) | 2018-04-11 | — | — | EP | claimed |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-01-21 | — | — | US | claimed |
| EP-2964028-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2016-01-13 | — | — | EP | claimed |
| WO-2014138279-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-09-12 | — | — | WO | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| EP-4728061-A1 | METHOD FOR SCREENING A MOLECULE FOR BINDING TO A PROTEIN OF INTEREST | Universität Basel (CH) | 2026-04-22 | — | — | EP | disclosed |
| CN-111699189-B | Modulators of beta-3 adrenergic receptors useful for treating or preventing heart failure and disorders associated therewith | 艾尼纳制药公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-1995032185-A1 | N-(3-AMINO-2-HYDROXYBUTYL)SULPHONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| EP-0555067-A1 | Hydroxylamine derivatives as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1993-08-11 | — | — | EP | disclosed |
| US-5202336-A | Lipoxygenase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-13 | — | — | US | disclosed |
| US-4699696-A | FROM MIXTURE OF CHLORIDE AND/OR SULFATE AND ADDITIVES CONSISTING OF AROMATIC SULFONAMIDES, SULFONIMID, MIXED CARBOXAMIDES-SULFONAMIDES AND ACETYLENE ALCOHOL | OMI INTERNATIONAL CORPORATION (US) | 1987-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | CA2 3196/4885CA1 4129/4885MMP1 1830/4885 |
| US-20190046513-A1 | COMBINATION THERAPIES OF HDAC INHIBITORS AND TUBULIN INHIBITORS | HDAC6, HDAC5, HDAC1 | CA2 576/4885CA1 1654/4885MMP1 439/4885 |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | BRAF, NRAS, RAF1 | CA2 3379/4885CA1 4764/4885MMP1 2945/4885 |
| US-20180169040-A1 | MICROTUBULE POLYMERIZATION MODULATORS FOR TREATING LMNA-RELATED DILATED CARDIOMYOPATHY | LMNB2, LMNB1, LMNA | CA2 4314/4885CA1 4863/4885MMP1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.